title: Genetic polymorphisms associated with endothelial function in nonarteritic anterior ischemic optic neuropathy.
abstract: OBJECTIVE
  To examine the relationship between nonarteritic anterior ischemic optic neuropathy (NAION) and genetic polymorphisms of enzymes influencing endothelial function.
  
  
  METHODS
  The subjects were 34 patients with NAION (mean age, 62.4 years old; 59% male) and 102 controls (mean age, 63.8 years old; 66% male). Genetic polymorphisms were investigated in three candidate genes associated with endothelial function: endothelin-1 (ET-1), angiotensin-converting enzyme (ACE), and methylenetetrahydrofolate reductase (MTHFR). The genotype distributions in the patients with NAION were compared with those in the controls.
  
  
  RESULTS
  There were no significant differences in the genotype distributions of the ACE I/D and MTHFR C677T polymorphisms between the NAION and control groups (p=0.261 and p=0.354, respectively), whereas the genotype distribution of the G/T (Lys198Asn) polymorphism of the ET-1 gene varied significantly between the groups (p=0.009). After adjusting for covariates, individuals with the TT genotype of the Lys198Asn polymorphism were more likely to develop NAION compared with those with the GG genotype (odds ratio=4.43, 95% confidence interval 1.33-14.73, p=0.015).
  
  
  CONCLUSIONS
  We found an increased prevalence of a G/T polymorphism of the ET-1 gene in patients with NAION. Our data suggest that this polymorphism may be an important risk factor in developing NAION in the Japanese population.
authors: Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan. tstmski@jikei.ac.jp
authors: Tsutomu
authors: T
authors: Sakai
authors: Keigo
authors: K
authors: Shikishima
authors: Masato
authors: M
authors: Matsushima
authors: Hiroshi
authors: H
authors: Tsuneoka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People / Q000235:genetics; D016022:Case-Control Studies; D019332:Endothelin-1 / Q000235:genetics*; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D054643:INDEL Mutation; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000235:genetics* / Q000503:physiopathology*; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
chemical_list: D019332:Endothelin-1; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D007703:Peptidyl-Dipeptidase A
references: Hypertension. 2003 Jan;41(1):163-7
references: 12511547
references: Am J Ophthalmol. 1994 Dec 15;118(6):766-80
references: 7977604
references: Ophthalmology. 2007 Apr;114(4):804-9
references: 17398323
references: Ophthalmology. 1999 Apr;106(4):739-42
references: 10201595
references: J Hum Hypertens. 2009 Dec;23(12):788-93
references: 19369957
references: Br J Ophthalmol. 1999 Nov;83(11):1287-90
references: 10535859
references: Am J Med. 1990 Jun;88(6):614-8
references: 2189304
references: Diabetes Res Clin Pract. 2000 Dec;50(3):195-202
references: 11106834
references: Arch Ophthalmol. 1997 Nov;115(11):1403-7
references: 9366670
references: Arch Ophthalmol. 1999 Mar;117(3):386-8
references: 10088818
references: Am J Ophthalmol. 1980 Sep;90(3):342-6
references: 7425050
references: Ann Behav Med. 2005 Aug;30(1):85-9
references: 16097909
references: Arch Ophthalmol. 1996 Nov;114(11):1366-74
references: 8906027
references: J Hypertens. 2001 Oct;19(10):1775-82
references: 11593097
references: Ophthalmic Genet. 2010 Sep;31(3):108-13
references: 20565247
references: Br J Ophthalmol. 1999 Sep;83(9):1083-7
references: 10460781
references: Mol Vis. 2008 Sep 15;14:1698-704
references: 18806884
references: Ophthalmology. 2008 Jul;115(7):1262
references: 18598821
references: Hypertension. 2001 Dec 1;38(6):1321-4
references: 11751711
references: N Engl J Med. 1990 Jan 18;322(3):205
references: 2403657
references: Ophthalmology. 1994 Apr;101(4):779-82
references: 8152775
references: Am J Ophthalmol. 1994 May 15;117(5):603-24
references: 8172267
references: Clin Neurosci. 1997;4(5):264-9
references: 9292253
references: Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):693-7
references: 19052769
references: Cardiovasc Hematol Disord Drug Targets. 2006 Mar;6(1):57-61
references: 16724936
references: Hypertension. 1999 May;33(5):1169-74
references: 10334806
references: Mol Vis. 2011;17:1254-60
references: 21633717
references: Lancet. 1989 Jul 1;2(8653):53-4
references: 2567834
references: Eye (Lond). 1995;9 ( Pt 1):85-8
references: 7713255
references: Nat Genet. 1995 May;10(1):111-3
references: 7647779
references: Am J Ophthalmol. 1983 Oct;96(4):478-83
references: 6624829
references: Kidney Int. 2000 Aug;58(2):513-9
references: 10916074
references: Clin Chem Lab Med. 2008;46(11):1575-80
references: 19012521
references: Coron Artery Dis. 2008 Nov;19(7):429-34
references: 18923236
references: Thromb J. 2005 Sep 07;3:13
references: 16144556
references: Arch Ophthalmol. 1985 Aug;103(8):1136-42
references: 4026642
references: Ophthalmology. 2011 May;118(5):959-63
references: 21439645
references: Am J Pharmacogenomics. 2001;1(3):189-201
references: 12083967
references: N Engl J Med. 2002 Dec 12;347(24):1916-23
references: 12477941